XALATAN (latanoprost ophthalmic solution) | Pfizer Medical Information

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

XALATAN Quick Finder

Temperature Stability Calculator
Report an adverse event or concern about the quality of a Pfizer product

To report and adverse reaction, or concern about the quality of a Pfizer product, please call Pfizer 1 866 723-7111 or visit www.healthcanada.gc.ca/medeffect or call Canada Vigilance Program at 1-866-234-2345.
Resources

Product Monograph

Download Product Monograph

Note: the information below includes the Part I: Health Professional Information.

Show All Hide All

Health Professional Information

Show Hide

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
ophthalmic	Latanoprost ophthalmic solution / 50 mcg/mL	benzalkonium chloride For a complete listing see Dosage Forms, Composition and Packaging section.

XALATAN (latanoprost) has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes, and growth of eyelashes. Pigmentation is expected to increase as long as XALATAN is administered. After discontinuation of XALATAN, pigmentation of the iris is likely to be permanent while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The effects of increased pigmentation beyond 5 years are not known. Patients who are expected to receive treatment in only one eye should be informed about the potential for increased pigmentation in the treatment eye and thus, heterochromia between the eyes.

XALATAN may gradually increase the pigmentation of the iris. This effect has predominantly been seen in patients with mixed coloured irides, i.e., blue-brown, grey-brown, green-brown or yellow-brown. The eye colour change is due to increased melanin content in the stromal melanocytes rather than to an increase in the number of melanocytes. This change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with XALATAN can be continued in patients who develop noticeably increased pigmentation, these patients should be examined regularly.

During clinical trials, the increase in brown iris pigment has not been shown to progress further upon discontinuation of treatment, but the resultant colour change may be permanent.

Hepatic/Biliary/Pancreatic

XALATAN has not been studied in patients with hepatic impairment and should, therefore, be used with caution in such patients.

Ophthalmologic

Macular edema, including cystoid macular edema, has been reported during treatment with XALATAN. These reports have mainly occurred in aphakic patients, in pseudophakic patients with torn posterior lens capsule, or in patients with known risk factors for macular edema. XALATAN should be used with caution in patients who do not have an intact posterior capsule or who have known risk factors for macular edema.

There is no experience with XALATAN in patients with inflammatory ocular conditions, inflammatory glaucoma, neovascular glaucoma or congenital glaucoma, and only limited experience with pseudophakic patients and in patients with pigmentary glaucoma.

XALATAN should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.

XALATAN should be used with caution in patients with a history of herpetic keratitis. XALATAN should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of ocular epithelial surface (see INFORMATION FOR THE CONSUMER).

This product contains benzalkonium chloride as a preservative, which may be absorbed by soft contact lenses. Remove contact lenses before administration of XALATAN. Contact lenses may be reinstalled 15 minutes after administering XALATAN.

Renal

XALATAN has not been studied in patients with renal impairment and should, therefore, be used with caution in such patients.

Respiratory

There is no experience in patients with severe or uncontrolled asthma. Such patients should therefore be treated with caution until there is sufficient experience (see ADVERSE REACTIONS and DETAILED PHARMACOLOGY - Human Pharmacodynamics for experience in patients with mild to moderate asthma).

Sexual Function/Reproduction

Fertility: Latanoprost has not been found to have any effect on male or female fertility in animal studies.

Skin

Eyelid skin darkening, which may be reversible, has been reported in association with the use of XALATAN (see WARNINGS AND PRECAUTIONS).

XALATAN may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Special Populations

Pregnant Women: Reproduction studies have been performed in rats and rabbits. In rabbits an incidence of 4 of 16 dams had no viable fetuses at a dose that was approximately 80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was approximately 15 times the maximum human dose (see TOXICOLOGY). XALATAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Women: The active substance in XALATAN and its metabolites may pass into breast milk and XALATAN should therefore be used with caution in nursing women (see TOXICOLOGY).

Pediatrics: The safety and efficacy of the use of XALATAN in children has not been established.

Did you find an answer to your question? Yes No

Adverse Reactions

Show Hide

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The ocular adverse events and ocular signs and symptoms reported in 5 to 15% of the patients on XALATAN (latanoprost) in the three 6 month, multi-centre, double-masked, active-controlled trials were blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased iris pigmentation and punctate epithelial keratopathy.

Local conjunctival hyperemia was observed: however, less than 1% of the XALATAN treated patients required discontinuation of therapy because of intolerance to conjunctival hyperemia.

In addition to the above listed ocular events/signs and symptoms, the following were reported in 1 to 4% of the patients: dry eye, excessive tearing, eye pain, lid crusting, lid edema, lid erythema, lid discomfort/pain and photophobia.

The most common systemic adverse events seen with XALATAN were upper respiratory tract infection/cold/flu which occurred at a rate of approximately 4%. Pain in muscle/joint/back, chest pain/angina pectoris and rash/allergic skin reaction each occurred at a rate of 1 to 2%.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

The following events were reported in less than 1% of the patients: conjunctivitis, diplopia and discharge from the eye.

During clinical studies, there were extremely rare reports of the following: retinal artery embolus, retinal detachment, and vitreous hemorrhage from diabetic retinopathy.

Post-Market Adverse Drug Reactions

Macular edema, including cystoid macular edema, has been reported during treatment with XALATAN. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. XALATAN should be used with caution in these patients. Upon discontinuation of XALATAN treatment, visual acuity has improved, in some cases with concurrent treatment with topical steroidal and non-steroidal anti-inflammatory drugs.

XALATAN has been reported to cause darkening, thickening and lengthening of eye lashes.

Based on spontaneous reports, rare cases of iritis/uveitis and very rare cases of darkening of the palpebral skin have been reported.

The following events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to XALATAN, or a combination of these factors, have been reported during postmarketing use of XALATAN in clinical practice and in the literature: eyelash changes (increased length, thickness, pigmentation of eyelashes, increased number of eyelashes and vellus hairs on the eyelid, curling of eyelashes, misdirected eyelashes sometimes resulting in eye irritation); eyelid skin darkening: periorbital and lid changes resulting in deepening of the eyelid sulcus; intraocular inflammation (iritis/uveitis); macular edema, including cystoid macular edema; corneal edema and erosions; iris cyst; pseudopemphigoid of ocular conjunctiva; localized skin reaction on the eyelid; photophobia; toxic epidermal necrolysis; infections and infestations: herpetic keratitis; nervous system disorders: dizziness and headache. Those events are reported voluntarily from a population of unknown size; therefore, estimates of frequency cannot be made. Rare cases of asthma, asthma aggravation, acute asthma attack and dyspnoea have been reported. There is limited experience from patients with asthma but latanoprost neither was found to affect pulmonary function when studied in a small number of steroid treated patients suffering from moderate asthma nor was it found to affect the pulmonary function, airway reactivity or β₂-responsiveness when studied in a small number of non-steroid treated asthma patients.

Cases of corneal calcification have been reported very rarely in association with the use of phosphate-containing eye drops in some patients with significantly damaged corneas.

Did you find an answer to your question? Yes No

Drug Interactions

Show Hide

Dosage And Administration

Show Hide

Overdosage

Show Hide

Action And Clinical Pharmacology

Show Hide

Mechanism of Action

XALATAN (latanoprost), a prostaglandin F_2α (13,14-dihydro-17-phenyl-18,19,20-trinor-PGF_2α isopropyl ester) analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure by increasing the outflow of aqueous humour. Studies in animals and man indicate that the main mechanism of action is increased uveoscleral outflow.

Glaucoma is a disease with characteristic optic nerve damage and a corresponding visual field defect. Increased intraocular pressure (IOP) is one of the main risk factors. However, disturbances in blood flow may also play a role in some cases. In ocular hypertension, patients may have increased IOP but without changes in the visual field or corresponding optic nerve damage.

Pharmacokinetics

XALATAN is a sterile, isotonic, buffered aqueous solution with a pH of approximately 6.7.

Each mL contains 50 μg of latanoprost, a colourless to slightly yellow oil. Latanoprost is an isopropyl ester prodrug which is well absorbed through the cornea and upon entering the aqueous humour is rapidly and completely hydrolysed to the biologically active acid. Studies in humans indicate that the peak concentration in the aqueous humour is reached about two hours after topical administration.

Following topical administration in monkeys, latanoprost is primarily distributed in the anterior segment, conjunctiva and eyelids with only minute quantities reaching the posterior segment. Reduction of IOP following a single dose in humans starts about 3 to 4 hours following topical administration, and the maximum effect is reached after 8 to 12 hours. Pressure reduction is maintained for at least 24 hours.

There is practically no metabolism of the acid of latanoprost in the eye. The plasma clearance is rapid and occurs in the liver. In humans, the half-life of the biologically active acid in plasma is approximately 17 minutes. In animal studies, the main metabolites were the 1,2-dinor and the 1,2,3,4-tetranor metabolites which exerted only weak or no biologic activity, and were excreted primarily in urine.

Did you find an answer to your question? Yes No

Storage And Stability

Show Hide

Dosage Forms, Composition And Packaging

Show Hide

Did you find an answer to your question? Yes No

Resources

website

Visit PfizerOriginals.ca

Didn’t find what you were looking for? Contact us.

Call 1-800-463-6001^*

^*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.

XALATAN (latanoprost)

XALATAN Quick Finder

Health Professional Information

SUMMARY PRODUCT INFORMATION

Indications And Clinical Use

Contraindications

Warnings And Precautions

General

Hepatic/Biliary/Pancreatic

Ophthalmologic

Renal

Respiratory

Sexual Function/Reproduction

Skin

Special Populations

Adverse Reactions

Clinical Trial Adverse Drug Reactions

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Post-Market Adverse Drug Reactions

Drug Interactions

Drug-Drug Interactions

Dosage And Administration

Dosing Considerations

Recommended Dose and Dosage Adjustment

Missed Dose

Administration

Overdosage

Action And Clinical Pharmacology

Mechanism of Action

Pharmacokinetics

Storage And Stability

Dosage Forms, Composition And Packaging

Resources

Your registration details are currently
being validated by the system.

{* message_registerTitle_1 *}

{* license_number_tooltipTitle *}

XALATAN (latanoprost)

XALATAN Quick Finder

Health Professional Information

SUMMARY PRODUCT INFORMATION

Indications And Clinical Use

Contraindications

Warnings And Precautions

General

Hepatic/Biliary/Pancreatic

Ophthalmologic

Renal

Respiratory

Sexual Function/Reproduction

Skin

Special Populations

Adverse Reactions

Clinical Trial Adverse Drug Reactions

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Post-Market Adverse Drug Reactions

Drug Interactions

Drug-Drug Interactions

Dosage And Administration

Dosing Considerations

Recommended Dose and Dosage Adjustment

Missed Dose

Administration

Overdosage

Action And Clinical Pharmacology

Mechanism of Action

Pharmacokinetics

Storage And Stability

Dosage Forms, Composition And Packaging

Resources

{* message_withExistingAccount *}

{* message_signInTitle *}

{* message_signInFormTitle *}

{* message_doNotHaveAccount *}

{* message_registerHeader *}

Your registration details are currently being validated by the system.

{* message_signIn *}

{* message_welcomeBack *}

{* message_welcomeBack *}

Social Registration

{* message_almostDone *}

{* registrationNewVerificationHeader *}

{* message_registerHeader *}

{* message_registerTitle_1 *}

{* license_number_tooltipTitle *}

Update to our terms of service

{* message_requestPasswordHeader *}

{* message_requestPasswordTitle *}

{* message_emailPasswordResetSent *}

Your registration details are currently
being validated by the system.